Glycopyrronium bromide/formoterol explained

Type:	combo
Component1:	Glycopyrronium bromide
Class1:	Muscarinic anticholinergic
Component2:	Formoterol
Class2:	Long-acting β2 agonist (LABA)
Tradename:	Bevespi Aerosphere
Dailymedid:	Glycopyrrolate and formoterol
Routes Of Administration:	By mouth (inhalation)
Atc Prefix:	R03
Atc Suffix:	AL07
Legal Ca:	Rx-only
Legal Ca Comment:	^[1]
Legal Us:	Rx-only
Legal Eu:	Rx-only
Legal Status:	Rx-only
Kegg:	D11036

Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).^{[2] [3]} It is a combination of glycopyrronium bromide and formoterol. It is inhaled.

The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.

Glycopyrronium bromide is a muscarinic receptor antagonist. This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.

Formoterol is a long-acting beta-2 agonist. It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.

Medical uses

Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).

History

Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016,^[4] and in the European Union in December 2018.

It is marketed by AstraZeneca.

Further reading

• Al-Salama ZT, Frampton JE . Glycopyrronium/Formoterol: A Review in COPD . Drugs . 79 . 13 . 1455–1466 . September 2019 . 31468315 . 10.1007/s40265-019-01186-x . 201655987 .
• D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR . 3 . New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology . Int J Chron Obstruct Pulmon Dis . 13 . 2805–2819 . 2018 . 30233171 . 6135066 . 10.2147/COPD.S113306 . free .

Notes and References

1. Web site: Regulatory Decision Summary for Bevespi Aerosphere . 23 October 2014 .
2. Web site: Bevespi Aerosphere- glycopyrrolate and formoterol fumarate aerosol, metered . DailyMed . 29 May 2019 . 8 May 2020.
3. Web site: Bevespi Aerosphere EPAR . European Medicines Agency (EMA) . 18 October 2018 . 8 May 2020.
4. Web site: Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol . U.S. Food and Drug Administration (FDA) . 16 February 2018 . 8 May 2020.